The race to eradicate the most common form of dwarfism is heating up. 

BioMarin Pharmaceutical was first across the FDA finish line a few years ago with a drug researchers called a “miracle.” But while the treatment, Voxzogo, stimulates bone growth, its effects on height are limited. And although Voxzogo sales are on a projected blockbuster path, BioMarin and other drug developers are charging ahead to find the next generation of treatments.

BioMarin revealed positive topline data from a different early-stage dwarfism candidate last month suggesting the new treatment could work better than Voxzogo — potentially teeing up its own competition. The biopharma may not have the market to itself for long, however. 

Today, we’re looking at a few of the other up-and-coming dwarfism treatments that could elevate outcomes.